Study of ANS014004 with EGFR-TKI for non-small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (ANS014004) combined with an EGFR-targeted therapy for people with advanced non-small cell lung cancer that has an EGFR mutation. It is for those whose cancer has gotten worse after standard treatments or who cannot take them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have advanced non-small cell lung cancer (stage IIIB, IIIC, or IV) that cannot be removed by surgery.
- Your cancer must have a specific EGFR gene mutation (common, uncommon, or exon 20 insertion).
- For patients in China, your tumor must have an increase in MET gene copies or MET protein levels after prior EGFR treatment.
- You must be able to do daily activities with little help (ECOG performance status 0 or 1).
- You must not have had certain prior treatments (like other MET inhibitors) or have uncontrolled health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests PLB1004, an oral medication that targets a specific gene mutation (EGFR) in non-small cell lung cancer. It may be an option if you have this mutation and are looking for a new treatment.
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests a new drug called ANS02 in people with non-small cell lung cancer (a common type of lung cancer) that has a specific genetic change called an EGFR mutation. The drug is designed to target and slow cancer growth in people with this mutation.
This trial tests whether adding SYS6010 to osimertinib before surgery works better than osimertinib alone for people with a type of lung cancer that has an EGFR mutation. The goal is to shrink the tumor and improve surgery outcomes.
This trial tests combining an EGFR-targeted pill (like osimertinib) with the intravenous drug bevacizumab for people with advanced non-small cell lung cancer that has an EGFR mutation and has not been treated before. The goal is to see if this combination works better when guided by a special blood test that finds cancer cells.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.